ğŸ‘ é¶æ ‡|SARS2çš„3CLè›‹ç™½

---
[TOC]

---
## SARS2 3CLè›‹ç™½åŠŸèƒ½
1. He J, Hu L, Huang X, et al. Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors[J]. International journal of antimicrobial agents, 2020, 56(2): 106055.
![](é¶æ ‡SARS2çš„3CLè›‹ç™½/é¶æ ‡SARS2çš„3CLè›‹ç™½_2022-12-19-20-34-15.png)
![](é¶æ ‡SARS2çš„3CLè›‹ç™½/é¶æ ‡SARS2çš„3CLè›‹ç™½_2022-12-19-20-50-13.png)

2. Kneller D W, Phillips G, Oâ€™Neill H M, et al. Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography[J]. Nature communications, 2020, 11(1): 1-6.
![](é¶æ ‡SARS2çš„3CLè›‹ç™½/é¶æ ‡SARS2çš„3CLè›‹ç™½_2022-12-19-21-49-24.png)


## SARS2 3CLè›‹ç™½ç»“æ„
**å®¤æ¸©ä¸‹çš„3CLè›‹ç™½æ´»æ€§ä½ç‚¹ç»“æ„**
1. Kneller D W, Phillips G, Oâ€™Neill H M, et al. Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography[J]. Nature communications, 2020, 11(1): 1-6.

## SARS2 3CLæŠ‘åˆ¶å‰‚
1. Iketani S, Forouhar F, Liu H, et al. Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors[J]. Nature communications, 2021, 12(1): 1-7. **å…±ä»·** [pdf](é¶æ ‡SARS2çš„3CLè›‹ç™½/s41467-021-22362-2.pdf)
![](é¶æ ‡SARS2çš„3CLè›‹ç™½/é¶æ ‡SARS2çš„3CLè›‹ç™½_2023-01-08-16-55-58.png)

2. Jin Z, Du X, Xu Y, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors[J]. Nature, 2020, 582(7811): 289-293. [pdf](é¶æ ‡SARS2çš„3CLè›‹ç™½/s41586-020-2223-y.pdf)
![](é¶æ ‡SARS2çš„3CLè›‹ç™½/é¶æ ‡SARS2çš„3CLè›‹ç™½_2023-01-08-19-04-02.png)
